Celldex Therapeutics, Inc. (CLDX) vs Mineralys Therapeutics, Inc. (MLYS)
A side-by-side comparison of Celldex Therapeutics, Inc. and Mineralys Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CLDX
Celldex Therapeutics, Inc.
$31.60HealthcareDelayed quote: Oct 6, 2026, 10:35 AM EDT
MLYS
Mineralys Therapeutics, Inc.
$22.54HealthcareDelayed quote: Oct 6, 2026, 10:35 AM EDT
Total return — CLDX vs MLYS
growth of $100 · dividends reinvested · last 4yCLDX -25.4% (-7.1%/yr)MLYS +26.4% (+6.0%/yr)MLYS compounded faster over this window
CLDX MLYS
CLDX vs MLYS: by the numbers
- •CLDX is the larger company ($2.10B vs $1.99B market cap).
- •Both run net losses; MLYS's is the smaller (0.00% vs -268385.71% net margin).
Metrics side by side
Valuation
| Metric | CLDX | MLYS |
|---|---|---|
| P/S ratio | 18770.68 | N/A |
| P/B ratio | 2.94 | 3.61 |
Profitability
| Metric | CLDX | MLYS |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -19160.00% | 0.00% |
| Net margin | -268385.71% | 0.00% |
| ROE | -42.07% | -63.45% |
| ROIC | -45.19% | -57.17% |
Growth (annualized)
| Metric | CLDX | MLYS |
|---|---|---|
| Revenue CAGR (5Y) | -58.05% | N/A |
| Total return CAGR (5Y) | -10.28% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.